1 The burden of nosocomial covid-19: results from the Wales multi-
2 centre retrospective observational study of 2518 hospitalised adults.
3

Authors

Mark J Ponsford, BMBCh MSc, Clinician Scientist [1,2]

Rhys Jefferies, MSc, National Respiratory Health Programme Manager[3]

Chris Davies, MB BS, BSc (Hons), MRCS, Professor [4]

Daniel Farewell, PhD, Reader in Statistics [5]

Ian R. Humphreys, PhD, Professor and Wellcome Trust Senior Research Fellow [1,6]

Stephen Jolles, BMBCh MSc PhD, Professor and Consultant Immunologist [2]

Sara Fairbairn, MBBcH, Consultant Respiratory Medicine [3,7]

Keir Lewis, MBBCh MD, Senior Lecturer and Consultant Respiratory Physician [8,9]

Daniel Menzies, MBBCh MD, Consultant Respiratory Medicine [10]

Amit Benjamin, MBBCh, Consultant Respiratory Medicine [11]

Favas Thaivalappil, MBBCh, Consultant Respiratory Medicine [12]

Simon Barry, MBBCh PhD, Consultant Respiratory Medicine [3,13]*

* Corresponding author, email: Simon.Barry@wales.nhs.uk

Affiliations
[1] Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, CF14 4XN

[2] Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, CF14 4XW

[3] Respiratory Health Implementation Group, Swansea University, SA2 8PP.

[4] Institute for Clinical Science and Technology, Cardiff, CF11 9LJ.

[5] Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, CF14 4XN

[6] Systems Immunity Research Institute, Cardiff University, Cardiff, CF14 4XN

[7] Department of Respiratory Medicine, Aneurin Bevan University Health Board, NP44 8YN.

[8] Department of Medicine, Prince Philip Hospital, Hywel Dda University Health Board, SA14 8QF

[9] College of Human & Health Sciences, Swansea University, SA2 8PP.

[10] Department of Respiratory Medicine, Betsi Cadwaladr University Health Board, LL18 5UJ

[11] Department of Respiratory Medicine, Cwm Taf University Health Board, CF72 8XR

[12] Department of Respiratory Medicine, Swansea Bay University Health Board, SA6 6NL

[13] Department of Respiratory Medicine, Cardiff and Vale University Health Board, CF 14 4XW

Abstract word count: 288; Article word count: 3549

Abstract

Objectives – To define the burden of nosocomial (hospital-acquired) novel pandemic coronavirus
(covid-19) infection among adults hospitalised across Wales.

Design - Retrospective observational study of adult patients with polymerase chain reaction (PCR)-
confirmed SARS-CoV-2 infection between 1st March – 1st July 2020 with a recorded hospital admission
within the subsequent 31 days. Outcomes were collected up to 20th November using a standardised
online data collection tool.

Setting – Service evaluation performed across 18 secondary or tertiary care hospitals.

Participants - 4112 admissions with a positive SARS-CoV-2 PCR result between 1st March to 1st July
2020 were screened. Anonymised data from 2518 participants were returned, representing over 60% of
adults hospitalised across the nation of Wales.

Main outcome measures - The prevalence and outcomes (death, discharge) for nosocomial covid-19,
assessed across of a range of possible case definitions.

Results - Inpatient mortality rates for nosocomial covid-19 ranged from 38% to 42% and remained
consistently higher than participants with community-acquired infection (31% to 35%) across a range
of case definitions. Participants with nosocomial-acquired infection were an older, frailer, and multi-
morbid population than those with community-acquired infection. Based on the Public Health Wales
case definition, 50% of participants had been admitted for 30 days prior to diagnostic testing.

Conclusions - This represents the largest assessment of clinical outcomes for patients with nosocomial
covid-19 in the UK to date. These findings suggest that inpatient mortality rates from nosocomial-
infection are likely higher than previously reported, emphasizing the importance of infection control
measures, and supports prioritisation of vaccination for covid-19 negative admissions and trials of post-
exposure prophylaxis in inpatient cohorts.

Trial registration – This project was approved and sponsored by the Welsh Government, as part of a
national audit and quality improvement scheme for patients hospitalised covid-19 across Wales.

Key Messages

What is already known on this topic

We searched PubMed and ISI Web of Science up until 31-December-2020 for studies reporting on
patient outcomes following hospital-acquired infection due to the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). We identified a range of case-definitions for hospital-acquired infection,
based on timing of diagnostic testing 5 to 15 days following admission. The largest and only multi-
centre study concluded individuals with nosocomial infection are at a lower risk of death from SARS-
CoV-2 than those infected in the community, however, was performed early in the pandemic and
utilised a conservative definition of nosocomial infection.

What this study adds

Our multi-centre observational study represents the largest assessment of clinical outcomes for patients
with nosocomial covid-19 in the UK to date, and suggests the burden of nosocomial SARS-CoV-2
infection has been underestimated. Nosocomial-infection occurred in older, frailer, and multi-morbid
individuals, and was consistently associated with greater inpatient mortality than amongst those who
were infected in the community across a spectrum of case-definitions. Our findings support
implementation of enhanced infection control measures to reduce this burden during future waves,
especially given the recent emergence of novel viral variants with enhanced transmissibility.
Furthermore, roughly half of the patients meeting the Public Health Wales definition of definite
nosocomial SARS-CoV-2 infection had been admitted for 30 days prior to diagnosis, highlighting a
potential window of opportunity for inpatient pre-exposure and/or post-exposure prophylaxis.

Introduction

Health-care-associated infections represent an enduring and serious threat to patient safety in hospital and healthcare facilities [1,2] and have been estimated to cost the National Health Service £1 billion every year.[3] The transmission of respiratory viruses such as influenza in the healthcare environment are a well recognised cause significant morbidity and mortality at the individual patient level,[4] however little is known regarding the significance of in-hospital (nosocomial) transmission of the novel pandemic coronavirus, SARS-CoV-2. Such information is essential to assess the effectiveness of recent infection control measure guidance.[5] A national report published by the Healthcare Safety Investigation Branch on 29th October 2020 stated: "*At the time of writing, there was no publicly available data to provide evidence of the scale of nosocomial of covid-19 in the NHS*".[6] In addition, acknowledgement of risk is timely to inform prioritisation of public health measures such as vaccination of healthcare workers and vulnerable populations, and decisions regarding continuation of routine NHS service provision.

We identified limited studies reporting on the prevalence and outcomes of medical patients' hospital-acquired covid-19 within the UK,[7-14] employing a range of case definitions and study design – restricting generalisability. The largest and only multi-centre cohort study was performed the by COPE (COVID-19 in Older PEople study) investigators, describing outcomes in 1564 patients admitted with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection across 11 hospitals (including 4 in Wales) between 27th February until 28th April 2020.[8] Applying a probabilistic case definition of nosocomial infection (admitted for at least 15 days before a SARS-CoV-2 diagnosis), Carter et al. estimated 12.5% contracted covid-19 in hospital. Mortality in the nosocomial patient group appeared comparable to those with likely community-acquired infection (27.0% and 27.2%, respectively), despite the older age and higher frailty of these patients.[8] Applying a similar case definition, Taylor et al found probable nosocomial cases represented 11.3% of confirmed cases within a major London trust admitted between 6th March to 12 April 2020; mortality was unreported in this study.[7] These reports preceded recognition of high-profile nosocomial outbreaks across several UK hospitals.[15,16] Thus, reliable estimates of the true impact of hospital-acquired covid-19 infection remain hampered by a paucity of publicly-available data at national and regional levels.[17]

Here, we update assessment of the relative burden of community- relative to nosocomial-acquired SARS-CoV-2 infection, utilising anonymised patient- and hospital-level data collected via the *National Pathway for Managing Covid-19 Infections in Secondary Care in Wales* initiative. Our primary aim was to describe inpatient case load and mortality across the nation of Wales in the context of probable infection source. Our secondary aim was to examine the significance of commonly used differing case definitions and statistical methodologies when interpreting these findings. Together these findings suggest that mortality from nosocomial infection may be higher than previously reported, emphasizing the importance of infection control measures to protect vulnerable inpatient cohorts, and directing prioritisation of pre- and post-exposure prophylactic measures.

Methods

Study design

Data were obtained as part of the National Pathway for Managing Covid-19 Infections in Secondary
Care in Wales initiative (www.covid-19hospitalguideline.wales.nhs.uk), which collects patient- and
site- level outcomes through the use of an online data collection tool, supporting guideline development
and subsequent audit cycles.

Setting

In each hospital in Wales a study lead was identified, who coordinated data collection. All 18 major
hospitals in Wales that admitted patients through emergency departments or medical assessment units
were included (Supplementary Table 1).

Participants

Positive SARS-CoV-2 polymerase chain reaction (PCR) results recorded between 1st March 2020 and
1st July 2020 with a record of hospital admission were obtained from Public Health Wales and used to
identify patients for retrospective notes review information by local clinical teams.

Data collection

Demographic variables with prognostic significance were collected as mandatory data fields for the
index admission using an online tool including: date of positive PCR swab collection, dates of
admission and discharge (when complete), patient age, sex, comorbidity count, and outcome (death or
discharge). Supplementary fields were also collected, as described in the text.

Outcomes

The primary outcome for analysis was descriptive in nature, with comparison of all-cause mortality rate
and cohort demographics based upon probable origin of SARS-CoV-2 infection. Secondary analyses
based on time to discharge or death were also investigated.

Missing data

Missing data were included in tables and descriptive analyses, allowing denominators to remain
consistent in calculations. Imputation of missing data was not performed.

Bias

Notes were selected randomly by site audit/record departments, to minimise potential for systematic
bias prior to data entry.

Quantitative variables

Frailty was assessed using the pre-admission Clinical Frailty Scale (CFS), as recommended by the
National Institute for Clinical Excellence.[18] For the purposes of the analyses, CFS scores were grouped
into clinically meaningful groups: 1-4, 5–6, and 7–9. Welsh Index of Multiple of Deprivation (WIMD)
was derived from the patients' post-code and evaluated by quartiles.

Statistical methods

Baseline demographic and clinical characteristics assessed at admission were grouped by outcome and
probable infection origin, based on a) clinician-recorded case definition, b) standardised case definitions
(Supplementary Table 2). Continuous variables are presented as median [inter-quartile range, IQR] and
categorical variables as n (%), unless otherwise stated. Time-to-event data were analysed using
cumulative incidence curves, acknowledging the competing risk of death or discharge. We used time in
hospital following a covid-19 diagnosis as a standard measure to avoid introducing survivorship-bias,
defining day 0 of the at-risk period as the most recent of either admission date or SARS-CoV-2
diagnostic testing.

Secondary statistical significance testing was performed according to the data encountered: For
univariate analysis of categorical data, such as sex, Fisher's exact or chi-square testing was performed,
comparing observed numbers for NC cases with numbers predicted by the ratio within the CAC sub-
group. For continuous data, Welch's t-tests were used if the assumptions of normality were met;
otherwise non-parametric Mann-Whitney U tests were employed. Multi-level logistic regression was
used to calculate odds ratios (ORs) and 95% Confidence Intervals (CI), including factors that occurred
before the outcome of interest to preserve causal order. Two-sided statistical significance was set at p
<0.05. Analysis were performed using R version 4.0.2 in RStudio (Version 1.3.959, R Foundation,
Vienna, Austria) with packages including *tidyverse*, and *survival* and GraphPad Prism (version 6.07).

Sensitivity analyses were performed to assess the effect of varying the clinical case definition for
nosocomial-acquired infection, and to minimise potential survivorship bias associated with previously-
used case definitions.

This project constitutes the evaluation/audit arm of the National Pathway for Managing covid-19
Infections in Secondary Care in Wales and was approved by Welsh Government. Information
governance policies on data protection were followed to record data securely at each site. Anonymised
data handling and storage was supported by The Institute of Clinical Science and Technology, Cardiff
UK.

Patient and public involvement: These data were generated as part of a rapid appraisal process and as
such patients were not involved in the setting of the research question or interpretation of the study.
Findings will be disseminated via the www.covid-19hospitalguideline.wales.nhs.uk tool.

Results

Participants

4112 adults hospitalised with a positive SARS-CoV-2 PCR result between 1st March to 1st July 2020
were screened from which clinical case information on 2594 case records were inputted (Supplementary
Figure 1: Study flowchart). Admission dates ranged from 25th March 2019, to 3rd July 2020, with the
last recorded discharge on 26th October 2020. A total of 76 individuals were excluded from the study
after data screening due to missing primary data fields. Reasons for exclusion were: age < 18 years or
not stated (n=27), admission date missing or incorrectly entered (n=15), date of PCR diagnosis missing
or outside of study period (n=16), and discharge date incorrectly entered (n=3). In addition, 15 cases
where the first PCR result exceeded 31 days of admission or discharge were excluded. This left 2518
patients for analysis with complete case records for primary fields, representing approximately 63% of
the total adult population hospitalised with covid-19 within the nation of Wales. For 10 of the 18
participating sites ≥ 80% coverage was achieved. Completeness of supplementary data fields was more
varied, with WIMD score available in 95.1% of cases, admission source in 2372 (93.8%), inpatient
ceiling of care decisions in 1976 (78.2%), and CFS in 1316 cases (52.1%).

Descriptive data

Admission features are summarised by outcome in Table 1. The cohort comprised a relatively elderly
population with a median age of 74 years [IQR 62.5-85.5; range 19-99]. Overall, more men (n= 1369,
54.4%) than women (n=1149, 45.6%) were admitted to hospital with a diagnosis of covid-19, although
this trend was reversed within the under 45 and over 85-year age groups (Table 1; Supplementary Table
3). A deprivation gradient was also apparent, with individuals from the most-deprived (lowest) WIMD
quartile over-represented within admissions (31.1%) relative to those in the least deprived quartile
(18.9%, Chi-squared test: p <0.0001).

Table 1: Demographics and clinical features at presentation
207

Prevalence and mortality rates by clinician recorded admission source

To investigate the impact of covid-19 infection origin on patient outcomes, we first examined mortality

by clinician-defined admission source, available in 2372 cases (93.8%); shown Table 2. Hospital-

acquired covid-19 was documented in 437 cases (17.3% of cohort, 37.8% mortality), comparable to

mortality following ambulance presentation (40.5%). Walk-in and GP referrals together accounted for

20.4% of the cohort and had the lowest estimated inpatient mortality rate (17.1-23.2%), comparable to

patients without a recorded admission source (26.3%). The small number of patients admitted from care

or nursing homes (n=52) showed an inpatient mortality rate of 46.2%.

Table 2: Patient outcomes by clinician-defined admission source

Nosocomial covid-19 is associated with greater mortality than community-acquired cases
across a range of standard case definitions
We next applied a definition of nosocomial covid-19 reported by the COPE-study investigators and
used by Public Health Wales,[8] based upon an interval exceeding 14 days between admission and SARS-
CoV-2 diagnostic testing (Supplementary Table 1). We identified 413 nosocomial cases, representing
16.4% of the cohort. Most patients (n=1610, 63.9 %) were diagnosed by PCR sampling conducted prior
to or within the first five days of admission date and were defined as community-acquired; 456 patients
(18.1% of total cases) had a positive PCR taken between 5 and 14 days after admission. By end of the
study period, 39.2% of patients with nosocomial-infection had died, compared to a case fatality rate of
31.6% in community-acquired covid-19 cases. This observation of greater mortality amongst NC
patients proved generalisable across the majority of admission sites (Figure 1). The median time from
SARS-CoV-2 diagnosis to discharge in community-acquired covid-19 cases was 7 days (IQR: 3.0-
15.0), compared to 17 days (IQR: 7.0-38.0) in patients with nosocomial-infection. Using this definition,
nosocomial cases had been admitted for a median of 30 days prior to diagnosis (IQR: 15.0-62.5), with
48 patients admitted for over 100 days. The median overall length of stay for patients with nosocomial
infection was 60 days (IQR: 34.0-98.5).

Figure 1: Inpatient mortality rates by admission hospital sites
236

As 95% of patients will display symptoms between 2 to 11.5 days of exposure,[19] the COPE-study
definition represents a conservative estimate of the burden of nosocomial-cases infection. We therefore
considered the effect on mortality and case numbers by varying the case definition across the incubation
period, taking admission as the earliest potential nosocomial exposure (Supplementary Table 4). As
shown in Figure 2A, inpatient mortality rates for nosocomial covid-19 ranged from 38% to 42% and
remained consistently greater than in patients with community-acquired infection (31% to 34%). By
contrast, varying the case definition resulted in significant changes in case numbers and deaths (Figure
2B/C). Applying the Public Health England case definition (diagnosis of SARS-CoV-2 made >7 days
following admission) identified 727 admissions and 301 deaths. This rose to 830 cases and 342 deaths
when patients with a date of PCR testing >5 days following admission was used to diagnose
nosocomial-covid-19.[20] Together, these findings indicate that whilst changing the case definition for
nosocomial-covid-19 has limited effect on case fatality rates, it significantly alters the number of
reported cases of nosocomial infection and total mortality.

Figure 2: Effect of varying case definitions on prevalence and crude mortality rate for
community- and nosocomial- SARS-CoV-2 infection.
252

Competing Risk analysis provides differing conclusions to Kaplan Meier
Kaplan Meier survival analysis has been utilised by several recent groups to compare outcomes for
hospital and community-acquired covid-19 in UK hospitals to date.[8,9] However, the differing discharge
kinetics observed in patients with nosocomial- and community-acquired covid-19 led us to question the
suitability of this statistical methodology without consideration of the competing risks of discharge to
death. As shown in Figure 3, nosocomial-infection is associated with a greater cumulative incidence of
inpatient mortality than community-acquired, in line with the crude case inpatient mortality rates
described. This contrast with Kaplan Meier analysis (Supplementary Figure 2), confirming the potential
for conflicting interpretations of the same data set when employing different statistical methodologies.

Figure 3: Competing risk analysis plot of nosocomial and community infection outcomes of
COVID-19 patients.
264

Patients with probable nosocomial COVID-19 infection are a more vulnerable population than
community acquired cases
We hypothesized that patients with nosocomial-covid-19 might represent a more vulnerable population,
a finding suggested by previous groups, but potentially confounded by introduction of selection bias
due to the requirement for a prolonged inpatient admission period within the case definition of
nosocomial-SARS-CoV-2 infection. To address this, we explored demographic and clinical
characteristics in patients based on a diagnostic cut-off of 2 days post-admission, a definition commonly
used for hospital-acquired bacterial pneumonia. Individuals with a positive SARS-CoV-2 test taken >2
days following admission were typically older and frailer, with a greater median CFS of 6 (IQR 4.5-
7.5), compared to 3 (IQR 1-5) in those with a positive SARS-CoV-2 test taken up to 2 days following
admission. Marked differences in multi-morbidity were evident, with 35.4% of "nosocomial" patients
having at least 4 comorbidities compared to 26.6% of "community-acquired" patients (Supplementary
Table 5). Together, this supports the hypothesis that age, frailty, and multi-morbidity are factors
associated with hospital-acquired covid-19, and not simply a reflection of the diagnostic definition.

Given the apparent vulnerability of the patient cohort developing nosocomial infection, we questioned
if ceiling of care decisions might impact upon patient outcomes. Returning to the COPE-study
definition, ceiling of care decisions were recorded in 1249 (77.6%) of community-acquired and 322
(78.0 %) of nosocomial-acquired covid-19. A ward-based ceiling of care (including consideration of
CPAP or NIV) was documented in 75.3% of nosocomial cases, compared to 58.8% of community-
acquired cases (Fisher's Exact Test p<0.0001, OR: 2.13, 95% CI: 1.58 to 2.87). Put another way, the
odds of a ward level ceiling of care being documented was twice as great in patients with nosocomial-
acquired compared to community-acquired covid-19. To determine the relative importance of this as a
predictor of adverse outcome, we performed logistic regression analysis with the binomial outcome of
death or discharge in nosocomial-acquired cases. In univariate analysis, older age and male sex were
both associated with increased odds of death; OR 1.02 (95% CI: 1.03 to 1.05) and OR 1.56 (95% CI:
1.05 to 2.33), respectively. Recorded ceiling of care at ward level was significantly associated with an
increased risk of mortality: OR 3.20 (95% CI: 1.88 to 5.43) when considered alone, but not following
adjustment for age, sex, index of multiple deprivation and comorbidities OR 1.39 (95% CI: 0.572 to
3.38). Taken together, these observations confirmed our expectation that patient with nosocomial-
acquired SARS-CoV-2 represented a more vulnerable cohort, and as such were less likely to be
managed using more invasive care such as intubation or CPAP. However, we found no evidence that a
ward-level ceiling of care was an independent predictor of mortality.

Monthly prevalence of nosocomial covid-19
We determined monthly trends for the frequency of total and new nosocomial diagnoses
(Supplementary Table 6). Between March and April 2020, the number of cases meeting the COPE
definition for nosocomial-infection across Wales increased from 97 to 216, paralleling the rise in total
covid-19 admissions. Nosocomial-infection represented 21.0% of new covid-19 diagnoses during May
(73/347 total cases), falling slightly to 18.5% in June. Similar nosocomial infection rates were observed
based on clinician-recorded nosocomial diagnoses, with a monthly prevalence between March to June
of 17.8% and 19.3%.

Discussion

Understanding the risk and burden of covid-19 infection within healthcare environments is essential to
direct risk mitigation strategies for the immediate future. In this work, we analysed a total of 2,518
patients with PCR-proven covid-19 infection admitted to hospitals across Wales. In contrast to previous
studies,[8] reported earlier in the pandemic, inpatient mortality rates were consistently greater in those
who likely acquired the virus in the context of hospital admission (37.9-42.2%), compared to
community-acquired infection (31.4-34.6%) across a range of case definitions. Such heightened
mortality rate estimates are in line with single centre reports from a major London teaching hospital
where definitely or probably hospital-acquired cases had a fatality rate of 36%.[13] Similarly, the monthly
prevalence estimates found in our study are also in line with the 20% modelled for a typical UK
hospital.[21]

Our study is also the first to investigate the impact of applying a range of case definitions when
quantifying the burden of hospital-acquired covid-19. By adopting a clinical case definition based on
the median incubation period for SARS-CoV-2 of 5 days,[20] we identified 14.2% additional cases, and
13.6% more deaths attributable to nosocomial covid-19 than with the >7-day threshold currently used
by Public Health England. This increased burden is likely an overestimate but may be relevant given
that even low-risk clinical assessment areas may contain patients with SARS-CoV-2.[22] Thus, in the
absence of sufficient isolation cubicles for patients undergoing assessment and adequately sensitive
rapid turn-around diagnostic testing, the risk of patient-to-patient transmission is likely to persist despite
infection control practices of cohorting and universal screening. We also confirm that patients with
hospital-acquired covid-19 appear a disproportionately vulnerable group, seemingly independent of
diagnostic delay from admission. Advanced age, frailty, and multi-morbidity are well-recognised risk
factors for adverse outcome in community-acquired covid-19.[23,24] We suggest increased frailty is also
likely to be causally associated with an increased personal care requirement and thus predispose to
nosocomial exposure of SARS-CoV-2 from healthcare workers, a conclusion supported by recent
whole-genome sequencing of nosocomial outbreaks.[14] As highlighted in a recent evaluation of serial
PCR screening in healthcare workers, 3% of those attending work tested positive for SARS-CoV-2.[25]
Serological studies suggest the rate of staff infection is far higher on wards with known nosocomial
outbreaks, in studies conducted in hospitals not undertaking staff screening.[26] Finally, we also
considered the impact of ceiling of care on outcome, as few other UK multi-centre studies have explored
this. Importantly, we found no evidence that ceiling of care determined outcome once clinical risk
factors were accounted for, a finding that may be reassuring for patients and families when discussing
this issue.

This study is primarily limited by its retrospective nature, which might predispose to ascertainment bias
(for instance, notes being more readily available for patients who have died than awaiting discharge).
This risk is common to other multi-centre studies,[8,23,24] and sites adopted random notes retrieval to
minimise this. We further sought to mitigate this by extending the data collection period well beyond
the end of the first wave, enabling capture of late discharges and including nosocomial outbreaks.
Record entry by a body of motivated clinicians followed a standardised online tool with a limited core
requirement, resulting in minimal missing core data. As a result, coverage exceeded 60% of hospital
admissions with covid-19 across the nation of Wales (and ≥80% in 10 of 18 participating sites). This
compares favourably to recent descriptive studies.[8,23,24] We recognise that our findings represent crude
inpatient mortality rate estimates, based on all-cause mortality. As the total number of patients at risk
of infection was unknown, they should not be used to infer the risk of acquiring SARS-CoV-2 within
hospital. Future studies making use of linked datasets are suggested to estimate excess mortality
associated with nosocomial infection and identify routes of transmission are required. However, with
the NHS facing winter-pressures and further surges in SARS-CoV-2 community circulation rates, our
findings serve as a timely reminder as to the dangers faced by patients within hospital as well as those
within care homes or shielding within the community. This concern is heightened by the spread of a
novel antigenic variant with evidence for enhanced transmissibility [27]

Together, our results highlight the burden associated with extremely infectious agents within the
healthcare environment. Although the incidence of nosocomial covid-19 cases decreased significantly
following the peak of community-acquired cases, the importance of enhanced infection control
measures cannot be overstated.[28] Indeed, current Public Health Wales data indicates an active rise in
probable hospital-acquired case numbers, mirroring the first wave.[29] We highlight the opportunity for
pre-exposure and post-exposure prophylactic measures, including vaccination and/or enrolment in
clinical trials employing pharmaceutical and biological antiviral agents such as antibody therapy.[30, 31]
This follows the observation that many of those dying with hospital-acquired covid-19 had typically
been in hospital for over a month prior to diagnosis of infection. Inpatient vaccination has long been
considered a missed opportunity for improving influenza vaccine uptake.[32] Finally, we caution that
research is urgently required to assess the efficacy of vaccination within vulnerable groups of
individuals within hospital and care homes, who are likely to differ from those enrolled in initial trials
in age, frailty, and immunocompetence.[33]

Data sharing

Data sharing will be considered by the management group upon written request to the corresponding
author. De-identified participant data or other prespecified data will be subject to a written proposal and
signed data sharing agreement.

Author contributions

SMB conceived the study and worked with RJ and CD to create the covid-19 guideline and the database.
MJP led data analysis supported by DF and wrote the first draft supervised by SB1, DF, SJ, and IH. CD
leads the Institute for Clinical Science and technology which created the digital interventions. MJP, RJ,
CD, and SMB have verified the underlying data and act as guarantors. All authors contributed scientific
and clinical guidance regarding study design, data collection, and have reviewed the final draft. The
corresponding author attests that all listed authors meet authorship criteria and that no others meeting
the criteria have been omitted.

Acknowledgements
This work uses data collected by the NHS and Public Health Wales as part of the routine care and
support for patients admitted with covid-19. We are extremely grateful to the frontline NHS junior
doctors for their commitment to inputting data from across Wales. We further acknowledge Gareth
Davies and Bea Addison from ICST for (Institute of Clinical Science and Technology) for database
management and coordinating the data collection.

Conflict of interest statement
The authors have no conflicts of interest to declare.

Sources of funding
The Welsh Government funds the Respiratory Health Implementation Group (RHIG) of which SB is
the lead and RJ the programme manager. RHIG fund the Institute for Clinical Science and Technology
(ICST) which created the digital interventions including the Welsh Hospital covid-19 guideline and the
on-line data collection tool. This work was partly funded by UKRI/NIHR through the UK Coronavirus
Immunology Consortium (UK-CIC).

MJP is supported by the Welsh Clinical Academic Training (WCAT) programme and a Career
Development Award from the Association of Clinical Pathologists and is a participant in the NIH
Graduate Partnership Program. IH is a Wellcome Trust Senior Research Fellow in Basic Biomedical
Sciences.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.

Table 1: Demographics and clinical features at presentation

Variable	Died (%)	Discharged (%)	Total (%)
Admission Hospital			2518
A	174 (40.6%)	255 (59.4%)	429 (17.0%)
B	165 (38.8%)	260 (61.2%)	425 (16.9%)
C	97 (39.8%)	147 (60.2%)	244 (9.7%)
D	78 (32.9%)	159 (67.1%)	237 (9.4%)
E	97 (42.9%)	129 (57.1%)	226 (9.0%)
F	46 (27.1%)	124 (72.9%)	170 (6.8%)
G	35 (21.9%)	125 (78.1%)	160 (6.4%)
H	48 (33.3%)	96 (66.7%)	144 (5.7%)
I	19 (22.6%)	65 (77.4%)	84 (3.3%)
J	22 (27.2%)	59 (72.8%)	81 (3.2%)
K	35 (43.2%)	46 (56.8%)	81 (3.2%)
L	24 (32.0%)	51 (68.0%)	75 (3.0%)
M	15 (22.4%)	52 (77.6%)	67 (2.7%)
N	24 (38.1%)	39 (61.9%)	63 (2.5%)
O	6 (25.0%)	18 (75.0%)	24 (0.9%)
P*	2 (25.0%)	6 (75.0%)	8 (0.3%)
Age Group (Years)			
<65	115 (14.7%)	667(85.3%)	782 (31.1%)
65-75	305 (44.3%)	383 (55.7%)	688 (27.3%)
75-85	275 (50.5%)	270 (49.5%)	545 (21.6%)
>85	192 (38.2%)	311 (61.8%)	503 (20.0%)
Sex			
Female	377 (32.8%)	772 (67.2%)	1149 (45.6%)
Male	510 (37.3%)	859 (62.7%)	1369 (54.4%)
Median comorbidity count (IQR)	3 (2-4)	2 (0.5 to 3.5)	2 (0.5 to 3.5)
Supplementary fields			
WIMD**			
Q1 – most deprived	265 (33.8%)	519 (66.2%)	784 (31.1%)
Q2	251 (37.9%)	411 (62.1%)	662 (26.3%)
Q3	163 (34.4%)	311 (65.6%)	474 (18.8%)
Q4 – least deprived	170 (35.9%)	304 (64.1%)	474 (18.9%)
WIMD unrecorded	38	86	124 (4.9%)
Clinical Frailty Score (CFS)			
1- Very Fit	21 (12.8%)	143 (87.2%)	164 (6.5%)
2- Fit	32 (16.1%)	167 (83.9%)	199 (7.9%)
3- Managing Well	47 (27.2%)	126 (72.8%)	173 (6.9%)
4- Vulnerable	63 (39.9%)	95 (60.1%)	158 (6.3%)
5- Mildly Frail	70 (52.6%)	63 (47.4%)	133 (5.3%)
6- Frail	117 (49.6%)	119 (50.4%)	236 (9.4%)
7- Severely Frail	88 (49.7%)	89 (50.3%)	177 (7.0%)
8- Very severely Frail	36 (62.1%)	22 (37.9%)	58 (2.3%)
9- Terminally Ill	7 (63.6%)	4 (36.4%)	11 (0.4%)
CFS unrecorded	406 (33.6%)	803 (66.4%)	1209 (48.0%)
Ceiling of Care			
Intensive Care	102 (30.0%)	238 (70.0%)	340 (13.5%)
Ward (CPAP)	98 (42.2%)	134 (57.8%)	233 (9.2%)
Ward (no CPAP)	574 (41.1%)	821 (58.9%)	1395 (55.4%)
Ceiling of Care unrecorded	113 (20.5%)	438 (79.5%)	554 (21.9%)

* Represents 3 combined centres (<5 patients each)
** Welsh Index of Multiple Deprivation (WIMD), 1= most deprived, 1,909= least deprived

416   Table 2: Patient outcomes by clinician-defined admission source

Admission Source	Died (%)	Discharged (%)	Total cases (%)
Ambulance	554 (40.6%)	810 (59.4%)	1364 (54.2%)
GP Practice	61 (23.4%)	200 (76.6%)	261 (10.4%)
Walk In	43 (17.1%)	209 (82.9%)	252 (10.0%)
Acquired in Hospital	164 (37.7%)	271 (62.3%)	435 (17.3%)
Other/not defined	41 (26.6%)	113 (73.4%)	154 (6.1%)
Care Home	24 (46.2%)	28 (53.8%)	52 (2.1%)

Figure 1: Inpatient mortality rates by admission hospital sites

Scatter plot showing inpatient mortality rates for patients with community-acquired covid-19 (circles);

and nosocomial covid-19 (triangles) by individual sites, with hospitals arranged by decreasing overall

case load are plotted from the left. For 11/15 sites, inpatient mortality rates for nosocomial cases

exceeds that of community acquired cases. Individual sites with fewer than 5 cases were excluded from

analysis.

Figure 2: Effect of varying case definitions on prevalence and crude mortality rate for

community- and nosocomial- SARS-CoV-2 infection.

Sensitivity analyses considering the effect on inpatient mortality rate (A), total case numbers (B), and

overall mortality burden (C) by varying the case definition across the incubation period, taking

admission as the earliest potential nosocomial exposure.

Figure 3: Competing risk analysis plot of nosocomial and community infection outcomes of

covid-19 patients.

Time to event analysis cumulative incidence analysis for the competing risks of discharge and

diagnosis, using the time from SARS-CoV-2 diagnosis. covid-19 origin is assigned by the commonly

used case definition, as outlined by Carter et al [8], nosocomial shown in red, community-acquired covid-

19- shown in black. Dotted lines: cumulative incidence of death, continuous lines: cumulative incidence

of discharge on probability scale. To deal with potential survivorship bias introduced by including CAC

patients tested prior to admission (who cannot reach discharge or death until admission), Day 0 is

defined as the more recent of day of admission or date of diagnostic SARS-CoV-2 testing.

References

1.   Burke JP. Infection Control — A Problem for Patient Safety. *New England Journal of Medicine*
2003; **348**(7): 651-6.
2.   Allegranzi B, Nejad SB, Combescure C, et al. Burden of endemic health-care-associated
infection in developing countries: systematic review and meta-analysis. *The Lancet* 2011; **377**(9761):
228-41.
3.   Senior K. Can we keep up with hospital-acquired infections? *The Lancet Infectious Diseases*
2001; **1**: 8.
4.   Godoy P, Torner N, Soldevila N, et al. Hospital-acquired influenza infections detected by a
surveillance system over six seasons, from 2010/2011 to 2015/2016. *BMC Infectious Diseases* 2020;
20(1): 80.
5.   NHS England and NHS Improvement. Minimising nosocomial infections in the NHS.
https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/06/C0586-minimising-
nosocomial-infections-in-the-nhs.pdf; 2020. Accessed 02-December-2020.
6.   Healthcare Safety Investigation Branch (HSIB). COVID-19 transmission in hospitals:
management of the risk – a prospective safety investigation. Independent report by the Healthcare
Safety Investigation Branch I2020/018. https://www.hsib.org.uk/documents/257/hsib-report-covid-
19-transmission-hospitals.pdf; 2020.
7.   Taylor J, Rangaiah J, Narasimhan S, et al. Nosocomial COVID-19: experience from a large acute
NHS Trust in South-West London. *Journal of Hospital Infection* 2020; **106**(3): 621-5.
8.   Carter B, Collins JT, Barlow-Pay F, et al. Nosocomial COVID-19 infection: examining the risk of
mortality. The COPE-Nosocomial Study (COVID in Older PEople). *Journal of Hospital Infection* 2020;
106(2): 376-84.
9.   Khan KS, Reed-Embleton H, Lewis J, Saldanha J, Mahmud S. Does nosocomial SARS-CoV-2
infection result in increased 30-day mortality? A multi-centre observational study to identify risk
factors for worse outcomes in COVID-19 disease. *J Hosp Infect* 2020; **107**: 91-4.
10.   Khonyongwa K, Taori SK, Soares A, et al. Incidence and outcomes of healthcare-associated
COVID-19 infections: significance of delayed diagnosis and correlation with staff absence. *Journal of
Hospital Infection* 2020; **106**(4): 663-72.
11.   Wake RM, Morgan M, Choi J, Winn S. Reducing nosocomial transmission of COVID-19:
implementation of a COVID-19 triage system. *Clin Med (Lond)* 2020; **20**(5): e141-e5.
12.   Brill SE, Jarvis HC, Ozcan E, et al. COVID-19: a retrospective cohort study with focus on the
over-80s and hospital-onset disease. *BMC Med* 2020; **18**(1): 194.
13.   Rickman HM, Rampling T, Shaw K, et al. Nosocomial transmission of COVID-19: a retrospective
study of 66 hospital-acquired cases in a London teaching hospital. *Clin Infect Dis* 2020.
14.   Lucey M, Macori G, Mullane N, et al. Whole-genome sequencing to track SARS-CoV-2
transmission in nosocomial outbreaks. *Clin Infect Dis* 2020.
15.   Lintern S. Hospitals battle coronavirus outbreaks as workforce shortages drive cancellation
fears. The Independent. 2020 10-OCTOBER-2020.
16.   Clarke O. Hospital Covid infections rise in Wales by 50% in week. BBC News Online. 2020.
17.   Iacobucci G. Covid-19: Doctors sound alarm over hospital transmissions. *BMJ* 2020; **369**:
m2013.
18.   National Institute for Clinical Excellence. NICE guideline 159 - COVID-19 rapid guideline: critical
care in adults. https://www-nice-org-uk.abc.cardiff.ac.uk/guidance/ng159/chapter/1-Admission-to-
hospital; 2020.
19.   Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-
19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of Internal Medicine*
2020; **172**(9): 577-82.
20.   Gupta RK, Marks M, Samuels THA, et al. Systematic evaluation and external validation of 22
prognostic models among hospitalised adults with COVID-19: An observational cohort study. *medRxiv*
2020: 2020.07.24.20149815.

21.   Evans S, Agnew E, Vynnycky E, Robotham JV. The impact of testing and infection prevention
and control strategies on within-hospital transmission dynamics of COVID-19 in English hospitals.
medRxiv 2020: 2020.05.12.20095562.
22.   Arif M, Maaref Doost M. Prevalence of COVID-19 Among Typical Ambulatory Care Patients in
a District General Hospital in the United Kingdom. *Cureus* 2020; **12**(11): e11398.
23.   Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with
covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort
study. *BMJ* 2020; **369**: m1985.
24.   Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with
COVID-19 (COPE): a multicentre, European, observational cohort study. *The Lancet Public Health* 2020;
5(8): e444-e51.
25.   Rivett L, Sridhar S, Sparkes D, et al. Screening of healthcare workers for SARS-CoV-2 highlights
the role of asymptomatic carriage in COVID-19 transmission. *Elife* 2020; **9**.
26.   Jones CR, Hamilton FW, Thompson A, Morris TT, Moran E. SARS-CoV-2 IgG seroprevalence in
healthcare workers and other staff at North Bristol NHS Trust: A sociodemographic analysis. *J Infect*
2020.
27.   Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England:
Insights from linking epidemiological and genetic data. *medRxiv* 2021: 2020.12.30.20249034.
28. Duy C, Nong VM, Van Ngo A, et al. Nosocomial Coronavirus Disease Outbreak Containment, Hanoi,
Vietnam, March-April 2020. *Emerg Infect Dis* 2021; **27**(1).
29.   Public   Health   Wales   Data   Dashboard.
https://public.tableau.com/profile/public.health.wales.health.protection#!/vizhome/RapidCOVID-
19virology-Public/Summary. Last accessed 06-Jan-2021.
30.   Hoy WE, Diwan, V. Trial of ivermectin for treatment and prophylaxis of COVID-19. *BMJ*;
2020;369:m1432.
31.   Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe
Covid-19 in Older Adults. *New England Journal of Medicine* 2021.
32.   Bratzler DW, Houck PM, Jiang H, et al. Failure to Vaccinate Medicare Inpatients: A Missed
Opportunity. *Archives of Internal Medicine* 2002; **162**(20): 2349-56.
33.   Andrew MK, McElhaney JE. Age and frailty in COVID-19 vaccine development. *The Lancet*
2020; **396**(10267): 1942-4.
526